Analysis of whether Sorafenib can effectively reduce tumor size

Sorafenib is a multi-target tyrosine kinase inhibitor that exerts anti-cancer effects mainly by inhibiting tumor cell proliferation and angiogenesis. It can target multiple signaling pathways such as VEGFR, PDGFR, RAF kinase, etc., thereby blocking the blood vessel supply required for tumor growth and limiting the tumor's access to nutrients and oxygen. Sorafenib has been shown to delay tumor progression and improve survival in a variety of tumors, including hepatocellular carcinoma, renal cancer, and thyroid cancer.

Although sorafenib has shown the effect of prolonging progression-free survival (PFS) and overall survival (OS) in multiple clinical studies, the proportion of it directly causing significant tumor shrinkage is relatively low. Taking advanced liver cancer as an example, the objective response rate of sorafenib (i.e., the proportion of patients whose tumor volume is reduced by more than 50%) is usually less than 5%. Most patients are in a stable disease state, that is, the tumor does not shrink significantly but does not continue to grow.

Since sorafenib mainly acts to delay tumor development rather than significantly shrink tumors, in practical applications it is more used to control the disease and delay progression, especially for mid-to-late stage patients who are inoperable or have poor response to other therapies. Although a few patients will experience partial response or even significant tumor shrinkage, in most cases it is a "cancer control" drug rather than a "cancer elimination" drug.

In order to improve the therapeutic effect of sorafenib, some studies have explored its combination with other drugs in recent years, such as combined treatment with immune checkpoint inhibitors or other targeted drugs. Some data show that the combination regimen may improve the response rate and tumor shrinkage effect. In addition, precision dosing and genetic testing can help identify patients who are more likely to benefit from sorafenib. Therefore, for patients pursuing tumor shrinkage, doctors may consider sorafenib combined with other regimens.

Reference materials:https://www.drugs.com/